Articles & Video
Venture Capital Has Advanced Innovation in China Life Science; It Needs to Do More
At the recent ChinaBio® Partnering Forum, a group of China VCs discussed their very vibrant field: $30 billion in VC investments last year, double the year before.
Biotech Startups: How to Succeed in a COVID-19 World
Taking a biotech company from concept, through clinical trials, and ultimately to market requires a perfect storm of good science, a sound investment, and the right management. This ebook is here to guide startups through this journey.
Let the Northern Lights Illuminate your BIO-Europe® Partnering
Making a plan for BIO-Europe digital in October? This time around we were almost going to be in Stockholm, one of the glittering capitals in the Nordics. But the world doesn’t seem quite ready to kick off its comfy Zoom slippers and try on some new work shoes to walk the walk, as well as talk the talk, for international biotech partnering. But even if we can’t be there in person, we can be there in spirit. Here’s some advice to add a little Nordic magic to your BIO-Europe partnering.
Alkermes: Driving Ambition in the Innovative Neuroscience and Oncology Space
In this interview, Blair Jackson, COO, Alkermes, speaks with Informa Connect’s Xconomy to discuss the rationale behind Alkermes’ evolving strategy in neuroscience and oncology and the ambition to be a major innovator in the competitive pharmaceutical landscape.
Mobilizing a Bio-Revolution
At the BIO-Europe Spring Opening Plenary “In the thick of it: Navigating beyond vaccine discovery”, Informa’s Eleanor Malone hosted a discussion with three leading authorities in biotech: Bayer’s Marianne De Backer, Pfizer’s Monika Vnuk, and Medicxi’s Francesco De Rubertis.
The COVID-19 pandemic has changed public perception of the European Biotech sector
In advance of BIO-Europe Spring® Digital 2021, we talked to conference attendees about recent changes in the sector and in their own companies to gain a glimpse of what the future might hold. As you would expect from this crowd, we got some very insightful answers and are happy to share them here.
SURVEY: Diversity, Equity and Inclusion in the Life Sciences 2021
Complete our survey on Diversity, Equity and Inclusion in the Life Sciences 2021 to get exclusive early access to the final report.
The Key to Playing Harmoniously at BIO-Europe Spring® Digital 2021
Can it really be almost a whole year since BIO-Europe Spring® 2020 went digital? In Groundhog Day, Bill Murray had become a concert pianist by this point in the film, having relived the same day several hundred times over, but wisely spending a little time each day to practice the piano, so he could successfully woo his partner of choice. So, a year on with digital partnering are you now skillful at Chopin or struggling at chopsticks?
Anchors Away: With Virtual Partnering, Biotech Buzz No Longer Tethered to Kendall Square
“It’s complicated,” said George Badescu, VP of business development at Heidelberg Pharma when I asked him if he prefers face-to-face or remote partnering conferences. “There are aspects of digital partnering I like but it can’t replace in-person interactions. I really miss them.”
Driving value in the era of biosimilars - What payers & manufacturers can do to support employers
We look at how big US employers are fostering broader adoption of biosimilar medications and what payers and manufacturers can do to support them.
Report: Partnering And Deal-Making in Pharma through the Pandemic
This Informa report explores how partnering and deal-making in the pharma industry has been impacted by COVID-19.
Biopharma Partnering and Financing Trends, H1 2020
With the help of Biomedtracker, analysts at Pharma Intelligence have taken a deep dive into the worldwide biopharma industry partnership and financial dealmaking during the first halves of 2019 and 2020. What they found is astounding and inside the new white paper.
REPORT: The Future of Healthcare Post COVID-19
In our latest report learn how healthcare organizations are adapting to succeed post COVID-19, from innovation to product development.
Interview: Promoting prosperity in the life science sectors of China and the UK
In this exclusive interview, Her Majesty’s Trade Commissioner for China at the Department for International Trade, John Edwards, discusses how China’s healthcare and life sciences markets are growing rapidly and are driven by increased demand and changes to regulations, plus much more.
Interview: Importance of diversity and partnering in global life sciences
ATLATL Innovation Cluster (IC) in the heart of Zhangjiang Pharma Valley. Its Founder and CEO, Dr. P.C. Zhu, designed it to be a launchpad for high-potential life sciences in China. In this interview with EBD Group he discusses the opportunities ATLATL provides and the importance of partnering in the life science industry.
Video Interview - Johnson & Johnson’s approach to external innovation
William N. Hait, MD, PhD, Global Head at Johnson & Johnson External Innovation gives an exclusive interview to Lucie Ellis, Executive Editor of In Vivo, Pharma Intelligence, ahead of ChinaBio® Partnering Forum Digital.
Interview – J&J’s multi-pronged approach to life science innovation, partnerships, and advanced technologies
Dr. Dan Wang, Head, Johnson & Johnson Innovation, Asia Pacific, and Dr. Sharon Chan, Head of JLABS @ Shanghai discuss its support of startups, interests in diverse disease areas, the importance of collaborations and much more in this exclusive interview with EBD Group.
SURVEY: Partnering and Deal-Making in Biopharma through the Pandemic
We are conducting a huge study to gauge perspectives around biopharma deal-making during COVID-19 and the commercial ramifications of the pandemic. Take part here.
“Sorry, I was on mute”: Tips for perfect life science partnering during upcoming digital events
The world has changed for us all due to COVID-19, and it can feel like we’ve jumped five years into the future in terms of online interactions using video-conference platforms to get things done. Companies need to adapt to survive and thrive in the new way of interacting with others.
REPORT: State of China Life Science - 2020 H1
Download this new exclusive ChinaBio® report with in-depth analysis of investment and partnering activity in China for 2020 H1 to discover the factors driving China life science investment. Learn how VC, IPO, and Partnering have rebounded despite COVID-19, but how M&A continues to slump.
Top Biotech Deals in China
Discover the deals transforming China biotech! More than $12 billion in biopharma financing, alliances, IPOs, and new funds have been generated so far this year in China. Learn the details of these deals when you read this new free infographic.
Pharma R&D Annual Review 2020
The researchers and analysts at Pharma Intelligence have taken the guess work out of figuring out how pharmaceutical research and development has progressed over the past few years and what you can expect in 2020. Pharma R&D Annual Review 2020 condenses the thorough analysis of all drugs in development by pharmaceutical companies, from those at the preclinical stage, through the various stages of clinical testing and regulatory approval, and up to and including launch.